☆ 4.7 Article

Primary lymphoma of the central nervous system: just DLBCL or not?

BLOOD (2009)

期刊

BLOOD

卷 113, 期 1, 页码 7-10

出版社

AMER SOC HEMATOLOGY

DOI: 10.1182/blood-2008-04-149005

关键词

-

类别

Hematology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Oncology

Relapsed Primary Central Nervous System Lymphoma: Current Advances

Kaiyan Tao, Xuefeng Wang, Xin Tian

Summary: Primary Central Nervous System Lymphoma (PCNSL) relapses are often derived from occult lymphoma cells, with treatment options including chemotherapy, radiation therapy, stem cell transplantation, targeted therapy, and immunotherapy. The overall prognosis is very poor, with early and varied clinical symptoms.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Challenges in the management of primary central nervous system lymphoma

Xuefei Sun, Liwei Lv, Yuchen Wu, Qu Cui, Shengjun Sun, Nan Ji, Yuanbo Liu

Summary: Primary central nervous system lymphoma (PCNSL) is a rare type of non-Hodgkin lymphoma. Stereotactic biopsy is the gold standard for diagnosis, but new auxiliary diagnostic methods such as cytokines and tumor circulating DNA show promise. Consolidation treatments, such as whole brain radiotherapy, autologous hematopoietic stem cell transplantation, and non-myeloablative chemotherapy, are being emphasized but there is uncertainty about the optimal strategy. This article reviews the diagnosis and treatment of PCNSL, focusing on research progress in consolidation therapy.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2023)

添加到收藏夹

Review Hematology

Advances in treatment of elderly primary central nervous system lymphoma

Nicolas Martinez-Calle, Lisa K. Isbell, Kate Cwynarski, Elisabeth Schorb

Summary: Managing primary central nervous system lymphoma in older individuals is a clinical challenge. Optimal therapy and adequate dose intensity are key issues, with high-dose methotrexate-based immunochemotherapy still being the recommended induction treatment. Utilizing geriatric assessment tools and considering individual performance status and comorbidities are important in personalized treatment approaches.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Review Oncology

Current and emerging therapies for primary central nervous system lymphoma

Yan Yuan, Tianling Ding, Shu Wang, Hong Chen, Ying Mao, Tong Chen

Summary: PCNSL is a rare type of lymphoma primarily treated with high-dose methotrexate-based chemotherapy, stem cell transplantation, and whole-brain radiotherapy. Future treatments may focus on targeted therapy and personalized medicine.

BIOMARKER RESEARCH (2021)

添加到收藏夹

Review Cell Biology

Understanding the molecular pathogenesis of primary central nervous system lymphoma by experimental animal models

Di Wu, Dahai Liu, Kensuke Tateishi, Fei Qi, Fang Yang, Chao Ke, Hua You

Summary: This review article presents the phenotypic and genotypic features of primary central nervous system lymphoma (PCNSL) tumor cells, and compiles the preclinical animal models of PCNSL. Researchers hope that these animal models will enhance the understanding of the molecular pathogenesis of PCNSL and accelerate the development of novel therapeutic strategies.

JOURNAL OF CELLULAR PHYSIOLOGY (2023)

添加到收藏夹

Review Hematology

Primary central nervous system lymphoma

Lauren R. Schaff, Christian Grommes

Summary: Primary central nervous system lymphoma (PCNSL) is a rare malignancy that affects the brain, spinal cord, or eye. Early diagnosis and timely treatment are crucial for optimal outcomes. Advances in high-dose methotrexate chemotherapy have improved prognosis, but relapse is still common. Novel treatments targeting abnormal pathways show promise for relapsed/refractory PCNSL.

BLOOD (2022)

添加到收藏夹

Review Oncology

Prognostic models in primary central nervous system lymphoma patients: A systematic review

Jelena Jelicic, Thomas Stauffer Larsen, Zoran Bukumiric, Karen Juul-Jensen, Bosko Andjelic

Summary: Various prognostic models have been proposed for PCNSL in the past decade, but consensus on the optimal model is still lacking. Age and performance status are important prognostic factors, but due to limitations such as small patient numbers and lack of validation, a universally accepted model has not been established. Future multicentre studies are needed to determine the optimal prognostic model for PCNSL.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)

添加到收藏夹

Article Oncology

Patients with Primary Central Nervous System Lymphoma Not Eligible for Clinical Trials: Prognostic Factors, Treatment and Outcome

Sabine Seidel, Michelle Margold, Thomas Kowalski, Alexander Baraniskin, Roland Schroers, Agnieszka Korfel, Eckhard Thiel, Michael Weller, Peter Martus, Uwe Schlegel

Summary: This study retrospectively analyzed the treatment, outcomes, and prognostic factors of 34 PCNSL patients who did not meet the inclusion criteria for clinical trials, comparing them to data from the largest study of PCNSL patients, the G-PCNSL-SG-1 trial. It found that younger age, receiving HDMTX treatment, and early response on MRI were favorable prognostic factors in patients not qualifying for clinical trials.

CANCERS (2021)

添加到收藏夹

Review Oncology

Evidence-based expert consensus on the management of primary central nervous system lymphoma in China

Tong Chen, Yuanbo Liu, Yang Wang, Qing Chang, Jinsong Wu, Zhiliang Wang, Daoying Geng, Jin-Tai Yu, Yuan Li, Xiao-Qiu Li, Hong Chen, Dongxiao Zhuang, Jianyong Li, Bin Wang, Tao Jiang, Lanting Lyu, Yuqin Song, Xiaoguang Qiu, Wenbin Li, Song Lin, Xinghu Zhang, Dehong Lu, Junqiang Lei, Yaolong Chen, Ying Mao

Summary: This consensus provides specific and evidence-based recommendations for the histopathological diagnosis, imaging examinations, treatment regimens, and management of complications in PCNSL patients.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

添加到收藏夹

Review Oncology

The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma

Ruben Van Dijck, Jeanette K. Doorduijn, Jacoline E. C. Bromberg

Summary: Primary central nervous system lymphoma (PCNSL) is a rare type of cancer limited to the central nervous system, with poor prognosis. The use of high-dose methotrexate-based chemotherapy is agreed upon for newly diagnosed patients, but the addition of rituximab for improving survival remains disputed. The available evidence of rituximab's effectiveness in PCNSL is still uncertain.

CANCERS (2021)

添加到收藏夹

Article Oncology

Radiotherapy or chemotherapy: a real-world study of the first-time relapsed and refractory primary central nervous system lymphoma

Yu Yang, Qing Li, Jingjing Ma, Hui Kang, Zhiguang Lin, Yang Wang, Yan Ma, Bobin Chen

Summary: This study aims to evaluate the efficacy of radiotherapy or chemotherapy in first-time relapsed or refractory progressed primary central nervous system lymphoma (PCNSL) and analyze the prognostic factors, exploring the differences between relapsed and refractory PCNSL. The results show that relapsed PCNSL responds well to inducing and salvage therapy and has a better prognosis compared to refractory PCNSL. Radiotherapy is effective for PCNSL after the first relapse or progression, and age, CSF protein level, and ocular involvement may be potential factors to predict prognosis.

FRONTIERS IN ONCOLOGY (2023)

添加到收藏夹

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

High 18F-FDOPA PET Uptake in Primary Central Nervous System Lymphoma

Betty Salgues, Elsa Kaphan, Elicia Molines, Gilles Brun, Eric Guedj

Summary: The study presented a 42-year-old female patient with primary central nervous system lymphoma (PCNSL) and strong uptake on F-18-FDOPA PET, similar to previous findings with C-11-MET PET. Therefore, PCNSL should be considered as a possible differential neoplastic diagnosis in cases of F-18-FDOPA uptake.

CLINICAL NUCLEAR MEDICINE (2021)

添加到收藏夹

Article Immunology

Prognostic impact of peripheral natural killer cells in primary central nervous system lymphoma

Zhiguang Lin, Jingjing Ma, Yan Ma, Qing Li, Hui Kang, Mengxue Zhang, Bobin Chen, Rong Xia

Summary: Circulating NK cells have a prognostic impact on primary central nervous system lymphoma (PCNSL). Patients with higher counts and proportions of NK cells have better prognosis, and the changes in NK cell counts before and after chemotherapy are also associated with prognosis. Higher NK cell counts are associated with longer overall survival, while higher fold changes in NK cell proportions and counts are associated with longer progression-free survival.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Article Genetics & Heredity

Molecular characteristics of immunocytes infiltration in primary central nervous system lymphoma

Linyun Zhang, Fei Sun, Xiaona Lu, Xiaotong Wang, Jie Wang, Jun Li, Yingsong Xu, Daqing Kou, Hongtao Lv, Bin Don

Summary: The tumor microenvironment in PCNSL is closely associated with tumor immune response. Higher ICI scores in PCNSL patients are correlated with a better tumor microenvironment, sensitivity to immunotherapy, and certain small molecule drugs. This study identified genes associated with ICI scores that may serve as important therapeutic and prognostic targets for PCNSL.

FRONTIERS IN GENETICS (2022)

添加到收藏夹

Article Medicine, General & Internal

Analysis of genomic alterations in primary central nervous system lymphoma

Xin He, Xiaotong Fan, Yongzhi Shan, Xinrui Ji, Lan Su, Yaming Wang

Summary: In this study, next-generation sequencing was used to investigate the genomic profile of primary central nervous system lymphoma (PCNSL). The most common mutation type and mutated genes in PCNSL were identified. Enrichment analysis revealed the involvement of mutated genes in various pathways and functional protein activities. This study provides insights into the molecular mechanisms of PCNSL and potential targets for diagnosis and precision medicine.

MEDICINE (2023)

添加到收藏夹

Letter Immunology

Response to Comment on Primary Central Nervous System (CNS) Lymphoma B Cell Receptors Recognize CNS Proteins

Manuel Montesinos-Rongen, Frauke Purschke, Anna Brunn, Martina Deckert

JOURNAL OF IMMUNOLOGY (2015)

添加到收藏夹

Letter Oncology

Analysis of mutational signatures in exomes from B-cell lymphoma cell lines suggest APOBEC3 family members to be involved in the pathogenesis of primary effusion lymphoma

R. Wagener, L. B. Alexandrov, M. Montesinos-Rongen, M. Schlesner, A. Haake, H. G. Drexler, J. Richter, G. R. Bignell, U. McDermott, R. Siebert

LEUKEMIA (2015)

添加到收藏夹

Article Clinical Neurology

Absence of Lymphatic Vessels in PCNSL May Contribute to Confinement of Tumor Cells to the Central Nervous System

Martina Deckert, Anna Brunn, Manuel Montesinos-Rongen, Reiner Siebert

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2016)

添加到收藏夹

Article Genetics & Heredity

The tumor epigenome - from gene regulation via tumor classification to therapy target

Ole Ammerpohl, Martina Deckert, Manuel Montesinos-Rongen

MEDIZINISCHE GENETIK (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia

Gero Knittel, Tim Rehkaemper, Darya Korovkina, Paul Liedgens, Christian Fritz, Alessandro Torgovnick, Yussor Al-Baldawi, Mona Al-Maarri, Yupeng Cun, Oleg Fedorchenko, Arina Riabinska, Filippo Beleggia, Phuong-Hien Nguyen, F. Thomas Wunderlich, Monika Ortmann, Manuel Montesinos-Rongen, Eugen Tausch, Stephan Stilgenbauer, Lukas P. Frenzel, Marco Herling, Carmen Herling, Jasmin Bahlo, Michael Hallek, Martin Peifer, Reinhard Buettner, Thorsten Persigehl, H. Christian Reinhardt

NATURE COMMUNICATIONS (2017)

添加到收藏夹

Article Oncology

Proteomic changes in cerebrospinal fluid from primary central nervous system lymphoma patients are associated with protein ectodomain shedding

Daniel Michael Waldera-Lupa, Omid Etemad-Parishanzadeh, Mareike Brocksieper, Nina Kirchgaessler, Sabine Seidel, Thomas Kowalski, Manuel Montesinos-Rongen, Martina Deckert, Uwe Schlegel, Kai Stuehler

ONCOTARGET (2017)

添加到收藏夹

Article Pathology

Enteric Murine Ganglionitis Induced by Autoimmune CD8 T Cells Mimics Human Gastrointestinal Dysmotility

Monica Sanchez-Ruiz, Anna Brunn, Manuel Montesinos-Rongen, Claudia Rudroff, Melanie Hartmann, Dirk Schlueter, Gabriele Pfitzer, Martina Deckert

AMERICAN JOURNAL OF PATHOLOGY (2019)

添加到收藏夹

Article Oncology

Array-based profiling of the lymphoma cell DNA methylome does not unequivocally distinguish primary lymphomas of the central nervous system from non-CNS diffuse large B-cell lymphomas

Julia Vogt, Rabea Wagener, Manuel Montesinos-Rongen, Ole Ammerpohl, Werner Paulus, Martina Deckert, Reiner Siebert

GENES CHROMOSOMES & CANCER (2019)

添加到收藏夹

Article Immunology

TLR signals license CD8 T cells to destroy oligodendrocytes expressing an antigen shared with a Listeria pathogen

Monica Sanchez-Ruiz, Noelle Katherine Polakos, Tobias Blau, Olaf Utermoehlen, Anna Brunn, Manuel Montesinos-Rongen, Thomas Huenig, Martina Deckert

EUROPEAN JOURNAL OF IMMUNOLOGY (2019)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Vimentin 3 Allows Differentiation between Normozoospermia and Oligoasthenoteratozoospermia

Timo Funke, Melanie von Brandenstein, Pia Paffenholz, Barbara Koditz, Tim Nestler, Jan Herden, Manuel Montesinos-Rongen, Evgenia Isachenko, Gohar Rahimi, Jochen W. U. Fries, Axel Heidenreich, Johannes Salem

DISEASE MARKERS (2019)

添加到收藏夹

Article Hematology

The process of somatic hypermutation increases polyreactivity for central nervous system antigens in primary central nervous system lymphoma

Manuel Montesinos-Rongen, Monica Terrao, Caroline May, Katrin Marcus, Ingmar Blumcke, Martin Hellmich, Ralf Kuppers, Anna Brunn, Martina Deckert

Summary: The mutational pattern of the B-cell receptor in PCNSL cells suggests antigenic selection and confinement in the CNS, supporting the pathogenesis of the disease. Abnormal GC reaction in PCNSL may increase self-/polyreactivity, facilitating BCR signaling via multiple CNS antigens and promoting tumor cell survival in the CNS.

HAEMATOLOGICA (2021)

添加到收藏夹

Article Pathology

Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy

Manuel Montesinos-Rongen, Anna Brunn, Armin Tuchscherer, Peter Borchmann, Elisabeth Schorb, Benjamin Kasenda, Janine Altmueller, Gerald Illerhaus, Maximilian Ruge, Mohammad Maarouf, Reinhard Buettner, Martin-Leo Hansmann, Michael Hallek, Marco Prinz, Reiner Siebert, Martina Deckert

JOURNAL OF MOLECULAR DIAGNOSTICS (2020)

添加到收藏夹

Review Oncology

Impact of a Faulty Germinal Center Reaction on the Pathogenesis of Primary Diffuse Large B Cell Lymphoma of the Central Nervous System

Manuel Montesinos-Rongen, Anna Brunn, Monica Sanchez-Ruiz, Ralf Kueppers, Reiner Siebert, Martina Deckert

Summary: The pathogenesis of primary CNS lymphoma (PCNSL) involves a failure in B cell differentiation and a lack of control during the entrance and within the germinal center (GC) stages. Targeted molecular studies have shown that activated pathways promote lymphoma cell proliferation, leading to tumor cells being trapped in a late B cell differentiation stage. This may contribute to the increased affinity of the lymphoma for the CNS.

CANCERS (2021)

添加到收藏夹

Article Oncology

An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities

Ruth Fluemann, Tim Rehkaemper, Pascal Nieper, Pauline Pfeiffer, Alessandra Holzem, Sebastian Klein, Sanil Bhatia, Moritz Kochanek, Ilmars Kisis, Benedikt W. Pelzer, Heinz Ahlert, Julia Hauer, Alexandra da Palma Guerreiro, Jeremy A. Ryan, Maurice Reimann, Arina Riabinska, Janica Wiederstein, Marcus Krueger, Martina Deckert, Janine Altmueller, Andreas R. Klatt, Lukas P. Frenzel, Laura Pasqualucci, Wendy Beguelin, Ari M. Melnick, Sandrine Sander, Manuel Montesinos-Rongen, Anna Brunn, Philipp Lohneis, Reinhard Buettner, Hamid Kashkar, Arndt Borkhardt, Anthony Letai, Thorsten Persigehl, Martin Peifer, Clemens A. Schmitt, Hans Christian Reinhardt, Gero Knittel

Summary: This study successfully recapitulated the characteristics of human ABC-DLBCL in a mouse model, indicating a cooperative role of Myd88 and BCL2 in lymphomagenesis and demonstrating substantial preclinical antilymphoma activity with combined BCL2 and PD-1 blockade.

BLOOD CANCER DISCOVERY (2021)

添加到收藏夹

Article Hematology

B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice

Gero Knittel, Paul Liedgens, Darya Korovkina, Jens M. Seeger, Yussor Al-Baldawi, Mona Al-Maarri, Christian Fritz, Katerina Vlantis, Svetlana Bezhanova, Andreas H. Scheel, Olaf-Oliver Wolz, Maurice Reimann, Peter Moeller, Cristina Lopez, Matthias Schlesner, Philipp Lohneis, Alexander N. R. Weber, Lorenz Truemper, Louis M. Staudt, Monika Ortmann, Manolis Pasparakis, Reiner Siebert, Clemens A. Schmitt, Andreas R. Klatt, F. Thomas Wunderlich, Stephan C. Schaefer, Thorsten Persigehl, Manuel Montesinos-Rongen, Margarete Odenthal, Reinhard Buettner, Lukas P. Frenzel, Hamid Kashkar, H. Christian Reinhardt

BLOOD (2016)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.